| dc.contributor.author |
Gaikwad, Anil Bhanudas |
|
| dc.date.accessioned |
2023-12-21T08:52:21Z |
|
| dc.date.available |
2023-12-21T08:52:21Z |
|
| dc.date.issued |
2017-09 |
|
| dc.identifier.uri |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830845/ |
|
| dc.identifier.uri |
http://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/13486 |
|
| dc.description.abstract |
Although cardioprotective effects of telmisartan are well explored, its effects on epigenetic alterations associated with type 2 diabetic (T2D) cardiomyopathy remain unmapped. Thus, the present study was designed to evaluate the potential of esculetin and telmisartan combination to reverse histone posttranslational modifications (PTMs) in curbing T2D cardiomyopathy. |
en_US |
| dc.language.iso |
en |
en_US |
| dc.publisher |
PMC |
en_US |
| dc.subject |
Pharmacy |
en_US |
| dc.subject |
Telmisartan |
en_US |
| dc.subject |
H2B histone |
en_US |
| dc.subject |
Type 2 diabetic (T2D) |
en_US |
| dc.title |
Telmisartan and esculetin combination ameliorates type 2 diabetic cardiomyopathy by reversal of H3, H2A, and H2B histone modifications |
en_US |
| dc.type |
Article |
en_US |